Antibody-mediated blockade of interferon-γ for the treatment of Crohn’s disease and psoriasis

Author：

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.14, Iss.9, 2004-09, pp. : 1373-1378

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y. Targan S.R.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M Korelitz Burton I

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

Recent developments in the pharmacological treatment of Crohn’s disease

By Srinivasan Radhika Lichtenstein Gary R

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 373-391

Informa Healthcare

Access to resources Recommend Favorite

Severe myalgia associated with mesalazine treatment in a child with Crohn’s disease

By Peršić Mladen Palčevski Goran Slavić Irena Vlahović-Palčevski Vera

European Journal of Clinical Pharmacology, Vol. 63, Iss. 3, 2007-03 ,pp. : 315-317

Springer Publishing Company

Access to resources Recommend Favorite

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohns Disease

By Peter D. Han Russell D. Cohen

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite